Welcome to our dedicated page for Jade Biosciences SEC filings (Ticker: JBIO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Jade Biosciences filings document a Nasdaq-listed clinical-stage biotechnology issuer developing antibody therapies for autoimmune diseases. Form 8-K reports furnish operating and financial results and attach corporate updates covering JADE101, JADE201, JADE301, research progress, and liquidity-related disclosures.
The company's proxy and material-event filings cover annual meeting matters, board and officer changes, compensatory arrangements, employment inducement stock plans, material agreements, private placement securities, common stock and pre-funded warrant terms, and other capital-structure disclosures. The filings also identify Jade as an emerging growth company with common stock registered under the Exchange Act.
Jade Biosciences, Inc. has a new large shareholder group reported on a Schedule 13G. Paradigm BioCapital Advisors LP, its general partner Paradigm BioCapital Advisors GP LLC, Senai Asefaw, M.D., and Paradigm BioCapital International Fund Ltd. together report beneficial ownership of shares of Jade Biosciences common stock.
The Adviser, its general partner, and Senai Asefaw each report 3,106,793 shares of common stock, representing 5.1% of the class, with sole voting and dispositive power over those shares. Paradigm BioCapital International Fund Ltd. separately reports 2,738,259 shares, or 4.5% of the class, also with sole voting and dispositive power. Percentages are based on 60,845,967 shares of common stock outstanding as of June 5, 2026, after an equity offering. Each reporting person disclaims beneficial ownership of any shares other than those directly owned.
Jade Biosciences reported that Janus Henderson Group Ltd. is the beneficial owner of 6,273,262 shares of common stock, representing 10.6% of the class as of 06/30/2026. The filing states the position reflects shared voting power and shared dispositive power over those shares.
The filing describes Janus Henderson as the ultimate parent of multiple registered asset managers that exercise investment and voting discretion on behalf of client accounts (the "Managed Portfolios"). The Asset Managers disclaim rights to receive dividends or sale proceeds from those Managed Portfolios; the filing notes no individual Managed Portfolio owns more than five percent of the class.
Jade Biosciences entered a JADE301 License Agreement with Paragon Therapeutics, securing a royalty-bearing, worldwide, exclusive, sublicensable license to certain monospecific antibodies against an undisclosed target for use across all human therapeutic areas.
The company may pay Paragon up to $22.0 million in development and regulatory milestones, including a $1.5 million development candidate nomination fee paid in January 2026 and a further $2.5 million on first dosing of a human in a Phase 1 trial.
On a product-by-product basis, Jade could owe up to approximately $20.1 million in sublicensing fees, plus low to mid-single-digit royalties on annual net sales of monospecific products and mid-single-digit royalties on multispecific products, with a 30% royalty reduction where no valid patent exists and royalties lasting at least 12 years from first sale or until patent expiry.
Paragon agrees not to start new campaigns for monospecific antibodies to the same target in the field for five years, and the agreement can be terminated on 60 days’ notice, for uncured material breach, or, where allowed by law, upon a party’s insolvency or bankruptcy.
Jade Biosciences, Inc. director Mark Eisner reported receiving a stock option grant that gives him the right to buy 47,675 shares of common stock at an exercise price of $21.81 per share. All 47,675 option shares were reported as held directly after the grant.
The option expires on June 24, 2036. According to the footnote, 1/36 of the total option shares vest monthly after the grant date, as long as Eisner continues to provide service to the company on each vesting date. This structure turns the award into ongoing, service-based compensation rather than an immediate, fully vested position.
Jade Biosciences, Inc. director Mark Eisner filed an initial Form 3, which is a statement of beneficial ownership for company insiders. This filing lists him as a director but does not report any buy, sell, or derivative transactions, indicating it is purely an initial ownership disclosure at this time.
Jade Biosciences, Inc. filed an 8-K announcing that its Board appointed Mark Eisner, M.D., M.P.H., as a Class I director effective June 25, 2026. He will serve until the 2028 annual meeting and join the Nominating and Corporate Governance Committee.
Dr. Eisner brings more than 25 years of leadership in clinical development and immunology, including senior roles at Vir Biotechnology, Sonoma Biotherapeutics, FibroGen and Genentech/Roche, as well as an academic career at UCSF. In connection with his appointment, he received a stock option to purchase 47,675 shares of Jade common stock under the 2025 Stock Incentive Plan, vesting in equal monthly installments over three years and accelerating upon a change in control, subject to continued service. He will also participate in the standard non-employee director compensation program and sign the company’s standard indemnification agreement. The company issued a press release with these details.
Jade Biosciences director Christopher W. Cain received a grant of stock options covering 34,843 shares of common stock at an exercise price of $15.22 per share. The option vests in full on the earlier of June 9, 2027 or the next annual stockholder meeting, subject to his continued service.
Under an arrangement with Fairmount Funds Management LLC, Cain holds this option for one or more Fairmount investment funds and must turn over any net cash or stock to Fairmount for those funds. Both Cain and Fairmount disclaim beneficial ownership of the option and underlying shares.
DOBMEIER ERIC reported acquisition or exercise transactions in this Form 4 filing.
Jade Biosciences, Inc. director Eric Dobmeier received a stock option grant covering 34,843 shares of common stock. The option has a strike price of $15.22 per share and expires on June 8, 2036. It vests in full on June 9, 2027 or at the next annual stockholder meeting, subject to his continued service.
Jade Biosciences director Klein Lawrence Otto received a grant of stock options covering 34,843 shares of common stock. These options have an exercise price of $15.22 per share and expire on June 8, 2036. The award vests in full on the earlier of June 9, 2027 or the next annual stockholder meeting, subject to his continued service. Following this compensation grant, he holds 34,843 derivative securities directly.
Jade Biosciences director Erin Lavelle received a stock option grant covering 34,843 shares of common stock. The option has an exercise price of $15.22 per share and expires on June 8, 2036. It vests in full on the earlier of June 9, 2027 or the next annual stockholder meeting, subject to her continued service.